Background
The so-called vasoreactivity testing is an inherent part of invasive diagnostics of pulmonary hypertension (PH) [1] . It has to be clarified -as a rule in the setting of an initial diagnosis -up to what extent a reversibility of PH exists depending on the extent of "remodeling" in the pulmonary vascular bed which, basically, is characterized by vascular wall thickening and increased collagen deposition /accumulation in the vascular wall, yet, as well, by thrombotic processes in microcirculation [2] .
The non fixed component of PH, which is marked by vasoconstriction, can be acutely influenced by vasodilators, particularly those being highly selective for pulmonary vessels, resulting, in the best case, in a pressure decrease of pulmonary artery (PA) while Cardiac Output (CO) remains constant, to an increase of CO without essential changes in pressure, or to both parallel which all finds expression in a decrease of pulmonary vascular resistance (PVR). Pressure decrease that is not accompanied by an increase in CO or, at least, constant CO, is not regarded as positive. Three criteria are described for a positive vasoreagibility testing (VRT) for a defined main group of precapillary pulmonary hypertension (PAH, WHO group I: decrease of mean pressure of PA by at least 10 mm Hg, absolute decrease of mean pressure below 40 mm Hg and improved, or, at least, constant CO [3] .
VRT is no standardized testing and is performed in a variety of ways at different sites. For instance, inhalable iloprost, inhalable NO, intravenous nitroprusside, intravenous milrinone, intravenous or sublingual Glycerol Trinitrate or sildenafil per os are used for the testing [4] .
Testing per os is unfavorable for reason of is belated effect so that from experience and depending on the individually differing time of resorption, a waiting period of more than 60 minutes can become necessary to be able to record the maximal vasodilatory effect. To what extent positive reactions in the setting of the testing help predicting positive effects under constant therapy of all the above mentioned inhalable or orally applicable substances remains unclear. It is merely validated that patients with idiopathic PAH showing a positive reaction on VRT can be successfully treated with calcium antagonists [5, 6] .
It is likewise uncertain whether the criteria defined for a successful testing for PAH are also valid for other forms such as PH in left heart failure (post capillary PH, WHO group II) [7, 8] .
Objectives
The present study seeks to clarify the following questions as a pilot study: Potential participants (patients with connective tissue disease or pulmonary primary disease, otherwise suspected pulmonary hypertension) are informed in detail about the study. A 24 hour time for consideration is followed by another discussion and, possibly, the patient's signature of the patient informed consent form. Afterwards, screening is performed via echocardiography and spiroergometry as well as the taking of blood samples (including NTproBNP). Invasive diagnostics (right heart catheterization) has to follow after a maximum of Data evaluation is performed at the study center Kerckhoff-Klinik, Bad Nauheim, Germany.
Patient informed consent signed by patient and informing physician is filed in a study binder. 
